Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.57 USD | -0.43% | -1.50% | +19.65% |
16/04 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
11/04 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
End-of-day quotes
Sector Bio Therapeutic Drugs
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
702M | - | |||||
106B | ||||||
23.47B | - | |||||
21.9B | - | |||||
18.77B | ||||||
17.85B |
- Stock Market
- Equities
- ANAB Stock
- Charts AnaptysBio, Inc.
- Sector Chart